News

After prolonged negotiations, AstraZeneca and Daiichi Sankyo are on the verge of finalizing a pricing agreement with the UK's drug-pricing regulator, potentially unlocking access to Enhertu—a breakthrough breast cancer therapy—for thousands of patients in England and Wales.

The Drug at the Centre of the Deal

Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo. It has demonstrated the ability to extend survival by approximately six months in certain patients with HER2-low breast cancer, a subtype that represents a significant portion of breast cancer diagnoses. The therapy has already gained widespread availability in other major markets, making the UK's delayed access a point of contention among patient advocacy groups and clinicians.

As per Astute Analytica, global HER2 positive breast cancer treatment market was valued at USD 8.56 billion in 2024 and is projected to reach USD 18.67 billion by 2033, growing at a CAGR of 9.1% over the forecast period.

Why the Deal Matters?

The impending agreement marks a potential resolution to a high-profile impasse that has drawn criticism from oncologists and patient groups alike. Previously, England's National Institute for Health and Care Excellence (NICE) had deemed Enhertu not cost-effective under its existing assessment framework. However, recent modifications to the UK's drug-pricing metrics—implemented as part of a trade agreement with the Trump administration—have altered the valuation landscape, creating fresh room for negotiation. 

If finalized, the deal would enable women in England and Wales with specific types of breast cancer to access a treatment that could meaningfully extend their lives. For many, Enhertu represents a critical therapeutic option where few alternatives exist, particularly in the HER2-low segment. 

Background: A History of Failed Talks

Negotiations over Enhertu's pricing have been fraught with difficulty. In November 2024, talks between the companies and NICE broke down, marking yet another failed attempt to reach a mutually acceptable price. That collapse became emblematic of a broader dispute concerning how the UK regulator assesses the value of innovative medicines, especially those offering modest but clinically meaningful survival gains. 

The renewed progress reported by Bloomberg News suggests both sides have found a middle ground—likely involving confidential discounts or outcome-based payment structures—that aligns with NICE's revised cost-effectiveness thresholds.

What's Next?

While the deal is described as "near," formal confirmation from AstraZeneca, Daiichi Sankyo, or NICE is still pending. Once approved, Enhertu could be rolled out through the National Health Service (NHS) in England and Wales, subject to final contracting and logistics.

For patients and providers, the development represents a long-awaited step toward equitable access to one of oncology's most promising recent advances. For the pharmaceutical industry, it signals a potential thaw in UK pricing tensions that have threatened to dampen the launch and uptake of innovative therapies.